The Wyandotte woman had worked at Blue Cross for 32 years and was denied a religious accommodation to the insurer's vaccine ...

As of December 31, 2020Source: Biomedtracker, National Institutes of Health, Pharmapremia and AllianceBernstein (AB) A case ...

November 6, 2024Personalis, Inc. misses on earnings expectations. Reported EPS is $-0.64 EPS, expectations were $-0.33.

Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its ...

Moderna said its newest Covid vaccine saw benefits after winning approval in the U.S. three weeks earlier than the last ...

Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

Leerink Partners analyst Mani Foroohar assigned a Sell rating on Moderna (MRNA – Research Report) on November 7 and set a price target of ...

Moderna posted a surprising third-quarter profit, driven by cost-cutting and higher-than-expected Covid vaccine sales.

Moderna reported a surprising third-quarter profit on Thursday, driven by cost reductions and stronger-than-expected sales of ...

The Cambridge-based company’s latest COVID shot was approved three weeks earlier than last year, according to a statement ...

Moderna stock rises as Q3 revenue beats estimates at $1.83 billion, driven by strong U.S. COVID-19 vaccine sales. EPS of $0.03 exceeds expectations.